These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23410145)

  • 1. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.
    Nakakeeto ON; Elliott BV
    Global Health; 2013 Feb; 9():6. PubMed ID: 23410145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
    Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
    BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: high, low or just right?
    Perriëns JH; Habiyambere V; Dongmo-Nguimfack B; Hirnschall G
    Antivir Ther; 2014; 19 Suppl 3():39-47. PubMed ID: 25310645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund.
    Vasan A; Hoos D; Mukherjee JS; Farmer PE; Rosenfield AG; Perriëns JH
    Bull World Health Organ; 2006 May; 84(5):393-8. PubMed ID: 16710550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
    Waning B; Kaplan W; King AC; Lawrence DA; Leufkens HG; Fox MP
    Bull World Health Organ; 2009 Jul; 87(7):520-8. PubMed ID: 19649366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
    Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
    Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing global antiretroviral procurement prices.
    Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
    BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.
    Waning B; Diedrichsen E; Jambert E; Bärnighausen T; Li Y; Pouw M; Moon S
    BMC Pediatr; 2010 Oct; 10():74. PubMed ID: 20950492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
    Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
    J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
    Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
    JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.
    Gupta A; Juneja S; Vitoria M; Habiyambere V; Nguimfack BD; Doherty M; Low-Beer D
    PLoS One; 2016; 11(10):e0164619. PubMed ID: 27736953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Development community.
    Liu Y; Galárraga O
    Health Policy Plan; 2017 Mar; 32(2):170-177. PubMed ID: 28207060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of COVID-19 on the global supply chain of antiretroviral drugs: a rapid survey of Indian manufacturers.
    Rewari BB; Mangadan-Konath N; Sharma M
    WHO South East Asia J Public Health; 2020 Sep; 9(2):126-133. PubMed ID: 32978345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
    Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
    PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.